Galectin Therapeutics (FRA:PHPN) Other Income (Expense) : €-0.42 Mil (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Galectin Therapeutics Other Income (Expense)?

Galectin Therapeutics's other income expense for the Galectin Therapeutics's pretax income for the three months ended in Dec. 2023 was €0.31 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.42 Mil.

Galectin Therapeutics Other Income (Expense) Historical Data

The historical data trend for Galectin Therapeutics's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galectin Therapeutics Other Income (Expense) Chart

Galectin Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Income (Expense)

Get a 7-Day Free Trial

0.12

0.53

-0.40

Galectin Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Income (Expense)	Get a 7-Day Free Trial															0.26	-0.72	0.45	-0.46	0.31

Galectin Therapeutics Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.42 Mil.

Galectin Therapeutics (FRA:PHPN) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Galectin Therapeutics (FRA:PHPN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (FRA:PHPN) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

GALT:USA

Address

4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071

Website

https://www.galectintherapeutics.com

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Galectin Therapeutics (FRA:PHPN) Headlines

No Headlines